Moderna, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Stéphane Bancel
- Full Time Employees
- 4,700
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 325 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Dec 7, 2018
- CIK
- 0001682852
- Website
- modernatx.com
- Similar Companies
- Business
- Moderna, Inc. (MRNA) develops and commercializes messenger RNA (mRNA) medicines and vaccines for infectious diseases, oncology, rare diseases, and other therapeutic areas; its core products include Spikevax (mRNA-1273), the COVID-19 vaccine approved for individuals 18 years and older; mRESVIA (mRNA-1345), the respiratory syncytial virus (RSV) vaccine for adults 60 years and older approved in the U.S., Europe, Canada, and Qatar; and mNEXSPIKE (mRNA-1283), the next-generation COVID-19 vaccine approved in the U.S.; the company advances a pipeline of over 45 development programs, including seasonal influenza and combination flu/COVID vaccines, cytomegalovirus vaccine candidates, individualized neoantigen therapies (INTs) such as intismeran autogene for oncology, and rare disease treatments targeting conditions like glycogen storage disease type 1a, with 36 ongoing clinical trials encompassing nine Phase 2 and Phase 3 oncology studies. Founded in 2010 and headquartered in Cambridge, Massachusetts, with manufacturing facilities in Norwood, Massachusetts, Moderna operates globally, partnering with governments and organizations in the U.S., UK, Canada, Australia, and Europe to support research, development, and commercial supply. Recent developments include closing a five-year $1.5 billion non-dilutive term loan facility with Ares Management Credit Funds in November 2025 to enhance liquidity to $7.1-7.6 billion; launching a three-year business strategy targeting up to 10% revenue growth in 2026 through geographic expansion and new product launches, aiming to grow its seasonal vaccine franchise from three to six approved products by 2028; investing $140 million to expand its Norwood facility for onshoring drug product capabilities, completing end-to-end domestic mRNA manufacturing; and discontinuing three pipeline assets—mRNA-1010 (seasonal influenza), mRNA-1083 (influenza/COVID combo), and mRNA-3745 (glycogen storage disease type 1a)—to prioritize high-impact programs amid cost management.
Company News
Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating
3 Stocks Whose Competitive Walls Tower Over Nvidia's
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More
Moderna: Massive Asymmetry About What The mRNA Is!
15 Stocks to Watch With Short Squeeze Potential
Why Moderna's Cancer Vaccine Matters to Investors
Stock Market Today, Sept. 1: Stocks Slide and Oil Surges Amid U.S.-Iran Tension
Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Moderna to Present at Upcoming Conferences in September 2026
Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?
Alyeska Investment Group L.P. Trims Stake in Moderna, Inc. $MRNA
Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of “Hold” by Brokerages
Is It Too Late to Buy Moderna Stock After Its 127% Surge?
‘This Breakup Saved You Far More Than Moderna Ever Could’: Orman to Woman Dumped After 180% Spike
This Moderna Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat
Moderna Stock Falls Friday: What's Going On?
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough